Meeting
2018 ASCO Annual Meeting
A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.
Authors
Matthew H. Taylor
Knight Cancer Institute, Oregon Health and Science University, Portland, OR
Matthew H. Taylor , Drew W. Rasco , Marcia S. Brose , Nicholas J. Vogelzang , Stephen Lane Richey , Allen Lee Cohn , Donald A. Richards , Daniel E. Stepan , Corina E. Dutcus , Matthew Guo , Robert Charles Shumaker , Emmett V. Schmidt , Lori J. Wirth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02501096
Citation
J Clin Oncol 36, 2018 (suppl; abstr 6016)
DOI
10.1200/JCO.2018.36.15_suppl.6016
Abstract #
6016
Poster Bd #
4
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase Ib/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer.
First Author: Marcia S. Brose
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
First Author: Matthew H. Taylor
Poster
2020 ASCO Virtual Scientific Program
Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
First Author: Lillian L. Siu
Poster
2018 ASCO Annual Meeting
Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results.
First Author: Vicky Makker